LAKE OSWEGO, Ore., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced it has entered into separate exchange agreements with several institutional holders of its outstanding warrants to surrender for cancellation of some of the warrants having “ratchet” price-based anti-dilution protection features in exchange for shares of Company common stock.
